Gregg Peterson

Gregg is CEO of Bexson Biomedical, a R&D stage pharmaceutical company focused on non-opioid therapies for pain management and mental health. He has over 20 years experience developing pharmaceutical, medical device, biologic and combination products, leading to commercial launch of over a dozen products globally. Gregg has held positions of increasing responsibility at both S&P500 companies and start-ups. He has a successful history running R&D programs in US, EU and AsiaPac, from ideation through Phase III clinical trials and to regulatory approval. Gregg is a veteran of multiple pharma startup companies with successful exits including Evolus (IPO), TargeGen (sale to Sanofi-Aventis) and Somaxon (IPO).